Significance of Early and Broad Testing of Tumor Mutations

Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP

Video Categories: NTRK Gene Fusions

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss how testing for tumor mutations early and broadly may lead to better treatment outcomes.

July 25, 2018

The Most Important Advances in Precision Medicine Being Presented at ASCO 2018

Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required [ Read More ]

January 20, 2016

Do Therapeutic Agents Affect Healthy Stem Cells?

Dr Wainberg and Dr Gerson ponder and provide opinions on whether these investigational therapies also target healthy cells.